Moderna (MRNA) PT Raised to $38 at BofA Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/31/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts MRNA Hot Sheet
Price: $221.72 -0.47%
Rating Summary:
6 Buy, 21 Hold, 4 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Rating Summary:
6 Buy, 21 Hold, 4 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Join SI Premium – FREE
BofA Securities analyst Alec Stranahan raised the price target on Moderna (NASDAQ: MRNA) to $38.00 (from $34.00) while maintaining a Underperform rating.
You May Also Be Interested In
- William Blair Downgrades Moderna (MRNA) to Market Perform
- Evercore ISI Downgrades Reddit (RDDT) to In Line, Removes From Tactical Outperform List
- Veralto Corp. (VLTO) PT Raised to $135 at Jefferies, 'Accelerating Core Growth into 2027'
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
